Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02591'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -68.57 Med: -28.1 Max: -17.41
Current: -30.59
During the past 3 years, Guangzhou Innogen Pharmaceutical Group Co's highest Return-on-Tangible-Asset was -17.41%. The lowest was -68.57%. And the median was -28.10%.
HKSE:02591's Return-on-Tangible-Asset is ranked better than 53.9% of 1410
companies
in the Biotechnology industry
Industry Median: -35.38
vs HKSE:02591: -30.59
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Guangzhou Innogen Pharmaceutical Group Co Return-on-Tangible-Asset Related Terms
Guangzhou Innogen Pharmaceutical Group Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co Return-on-Tangible-Asset Chart
Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend
Dec23
Dec24
Dec25
Return-on-Tangible-Asset
-68.57
-17.41
-28.10
Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Return-on-Tangible-Asset
0.00
-13.85
-21.83
-27.14
-35.67
HKSE:02591 vs VRTX, REGN, MRNA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Innogen Pharmaceutical Group Co Return-on-Tangible-Asset vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -35.67% mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Return-on-Tangible-Asset of -35.67% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #650 out of 1410 companies in the Biotechnology industry, placing it in the top 46.1%.
Is Guangzhou Innogen Pharmaceutical Group Co's Return-on-Tangible-Asset too high?
Guangzhou Innogen Pharmaceutical Group Co's current Return-on-Tangible-Asset is -35.67%. Based on the distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #650 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #650 out of 1410 companies for Return-on-Tangible-Asset. This puts Guangzhou Innogen Pharmaceutical Group Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. Guangzhou Innogen Pharmaceutical Group Co's current Return-on-Tangible-Asset is -35.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Return-on-Tangible-Asset of -35.67%. The current Return-on-Tangible-Asset is -35.67%. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Return-on-Tangible-Asset is -35.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
8GF Score
Get the complete analysis for HKSE:02591
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02591 has been successfully added to your 
